Emma Pollard
Human Resources Officer chez CORONADO GLOBAL RESOURCES INC.
Fortune : 52 698 $ au 31/03/2024
Profil
Emma Pollard is currently the Chief People & Sustainability Officer at Coronado Global Resources, Inc. She previously worked as the Director-Human Relations, Australia & New Zealand at Alphapharm Pty Ltd.
from 2011 to 2013.
From 2013 to 2017, she served as the Head-European Human Resources Operations at Mylan NV.
Emma also held the position of General Manager-People & Sustainability at Wesfarmers Ltd.
Additionally, she worked as the Executive General Manager-Human Resources at Capral Ltd.
from 2005 to 2011.
Prior to that, she was the Human Resources Manager-Metro Politan Division at Rail Infrastructure Corp.
Emma completed her undergraduate degree at the University of Sunderland.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/04/2024 | 6 462 ( 0,00% ) | 52 698 $ | 31/03/2024 |
Postes actifs de Emma Pollard
| Sociétés | Poste | Début |
|---|---|---|
| CORONADO GLOBAL RESOURCES INC. | Human Resources Officer | 01/10/2018 |
Anciens postes connus de Emma Pollard
| Sociétés | Poste | Fin |
|---|---|---|
Mylan NV
 Mylan NV Pharmaceuticals: MajorHealth Technology Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom. | Corporate Officer/Principal | 01/09/2017 |
Alphapharm Pty Ltd.
 Alphapharm Pty Ltd. Pharmaceuticals: GenericHealth Technology Alphapharm has been developing and making generic medicines in Australia for more than 25 years. Millions of Australians take an Alphapharm generic medicine every day. In fact, It has become the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme and Australia's leader in generic medicines. Alphapharm medicines are available Australia-wide. Alphapharm medicines are made to the highest global quality standards and exported to more than 50 countries, including those in Europe and the US. Globally, Alphapharm is part of Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third-largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. | Corporate Officer/Principal | 01/01/2013 |
| CAPRAL LIMITED | Human Resources Officer | 01/01/2011 |
| WESFARMERS LIMITED | Human Resources Officer | - |
| Rail Infrastructure Corp. | Human Resources Officer | - |
Formation de Emma Pollard
| University of Sunderland | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| WESFARMERS LIMITED | Retail Trade |
| CAPRAL LIMITED | Non-Energy Minerals |
| CORONADO GLOBAL RESOURCES INC. | Energy Minerals |
| Entreprise privées | 3 |
|---|---|
Mylan NV
Mylan NV Pharmaceuticals: MajorHealth Technology Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom. | Health Technology |
Alphapharm Pty Ltd.
Alphapharm Pty Ltd. Pharmaceuticals: GenericHealth Technology Alphapharm has been developing and making generic medicines in Australia for more than 25 years. Millions of Australians take an Alphapharm generic medicine every day. In fact, It has become the largest supplier of medicines to the government subsidised Pharmaceutical Benefits Scheme and Australia's leader in generic medicines. Alphapharm medicines are available Australia-wide. Alphapharm medicines are made to the highest global quality standards and exported to more than 50 countries, including those in Europe and the US. Globally, Alphapharm is part of Mylan Inc., which provides products to customers in more than 140 countries and territories, ranks among the leading diversified generic and specialty pharmaceutical companies in the world. The company maintains one of the industry's broadest - and highest quality - product portfolios, supported by a robust product pipeline; owns a controlling interest in the world's third-largest active pharmaceutical ingredient manufacturer; and operates a specialty business focused on respiratory and allergy therapies. | Health Technology |
| Rail Infrastructure Corp. |
